ArticlePloS one2026
Mechanical ventilation as an independent risk factor for mortality in COVID-19-related ARDS: A secondary analysis using propensity score weighting.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe optimal role of invasive mechanical ventilation (IMV) in COVID-19-related acute respiratory distress syndrome (C-ARDS) remains uncertain. During the pandemic, many patients with ARDS were managed without IMV, creating a unique opportunity to examine whether IMV is an independent risk factor for mortality rather than a marker of disease severity alone. This study aimed to estimate the adjusted association between IMV and in-hospital mortality in patients with C-ARDS.
methodsWe performed a secondary analysis of a previously published prospective cohort of adults hospitalized with confirmed C-ARDS at a tertiary center located at high altitude (2,640 m, Bogotá, Colombia). Covariate balancing propensity scores (CBPS) were used to derive inverse probability of treatment weights (IPTW). Weighted logistic regression was then applied to estimate the average treatment effect (ATE) of IMV on in-hospital mortality. As a secondary objective, respiratory mechanics during the first 5 days of IMV were described to evaluate adherence to lung-protective ventilation.
resultsA total of 1,724 patients with complete data were included; median age was 68 years, 65.9% were male, and overall mortality was 44.8%. Of these, 897 patients (52.0%) required IMV. Mortality differed markedly between groups: 65% in ventilated patients vs. 22% in non-ventilated patients. After IPTW adjustment, IMV remained independently associated with higher mortality (ATE-adjusted OR 7.67; 95% CI 6.20-9.48; p < 0.001). Respiratory mechanics were available for 838 (93.4%) ventilated patients. Median tidal volume, plateau pressure, and driving pressure were initially within protective ventilation targets; however, non-survivors showed small progressive increases in plateau and driving pressures over time.
conclusionsIn this propensity score-weighted cohort of patients with COVID-19-related ARDS, IMV was strongly associated with in-hospital mortality after adjustment for measured confounders. Ventilatory parameters were generally within protective ranges during the early course of ventilation, although non-survivors showed less favorable longitudinal pressure trajectories. These findings support careful patient selection, optimization of non-invasive support when feasible, and strict adherence to lung-protective ventilation strategies. Residual confounding cannot be excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.